The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat Topic 3/23: What Is a High-Value Cancer Drug?
- #LCSM Chat Topic 3/9: Test Tumors to Target Lung Cancer
- #LCSM Chat Topic 2/23:Living with Cancer–What’s in your Toolbox?
- #LCSM Chat Topic 2/9: Flip the Clinic for Lung Cancer–What Works Best?
- #LCSM Chat Topic 1/26: Education and Shared Decision Making for Cancer Patients in the Era of Fake News and Post-Truths
#ASCO16 #LCAM14 ALK ASCO 2016 biomarker cancer treatment plans clinical trials drug costs Drugs EGFR epatients immunotherapy insurance LDCT lung cancer lung cancer awareness month lung cancer community lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment PCORI self-advocacy shared decision making World Cancer Day